Additional cytogenetic abnormalities and variant t(9;22) at the diagnosis of childhood chronic myeloid leukemia: The experience of the International Registry for Chronic Myeloid Leukemia in Children and Adolescents
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články
PubMed
28497898
DOI
10.1002/cncr.30767
Knihovny.cz E-zdroje
- Klíčová slova
- Philadelphia-positive, child, chronic myeloid leukemia, cytogenetic, imatinib,
- MeSH
- analýza přežití MeSH
- chromozomální aberace statistika a číselné údaje MeSH
- chronická myeloidní leukemie diagnóza farmakoterapie genetika mortalita MeSH
- genetická predispozice k nemoci epidemiologie MeSH
- internacionalita MeSH
- Kaplanův-Meierův odhad MeSH
- kvantitativní polymerázová řetězová reakce metody MeSH
- lidé MeSH
- lidské chromozomy, pár 22 genetika MeSH
- lidské chromozomy, pár 9 genetika MeSH
- následné studie MeSH
- neparametrická statistika MeSH
- přežití bez známek nemoci MeSH
- protokoly protinádorové kombinované chemoterapie terapeutické užití MeSH
- registrace MeSH
- retrospektivní studie MeSH
- rozvrh dávkování léků MeSH
- výsledek terapie MeSH
- vztah mezi dávkou a účinkem léčiva MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
BACKGROUND: In the adult population with newly diagnosed chronic myeloid leukemia (CML), variant translocations are usually not considered to be impairing the prognosis, whereas some additional cytogenetic abnormalities (ACAs) are associated with a negative impact on survival. Because of the rarity of CML in the pediatric population, such abnormalities have not been investigated in a large group of children with CML. METHODS: The prognostic relevance of variant t(9;22) and ACAs at diagnosis was assessed in 301 children with CML in the chronic phase who were enrolled in the International Registry for Chronic Myeloid Leukemia in Children and Adolescents. RESULTS: Overall, 19 children (6.3%) presented with additional cytogenetic findings at diagnosis: 5 children (1.7%) had a variant t(9;22) translocation, 13 children (4.3%) had ACAs, and 1 had both. At 3 years, for children with a classic translocation, children with ACAs, and children with a variant t(9;22) translocation who were treated with imatinib as frontline therapy, the probability of progression-free survival (PFS) was 95% (95% confidence interval [CI], 91%-97%), 100%, and 75% (95% CI, 13%-96%), respectively, and the probability of overall survival (OS) was 98% (95% CI, 95%-100%), 100% (95% CI, 43%-98%), and 75% (95% CI, 13%-96%), respectively. No statistical difference was observed between the patients with classic cytogenetic findings and those with additional chromosomal abnormalities in terms of PFS and OS. CONCLUSIONS: In contrast to adults with CML, additional chromosomal abnormalities observed at diagnosis do not seem to have a significant prognostic impact. Cancer 2017;123:3609-16. © 2017 American Cancer Society.
Children's Cancer Research Institute and St Anna Children's Hospital Vienna Austria
Department of Pediatric Hematology Robert Debré Hospital Paris France
Department of Pediatric Hematology Uludağ University Hospital Görükle Bursa Turkey
Department of Pediatric Oncology University Children's Hospital Bratislava Slovakia
Department of Pediatrics Carl Gustav Carus University Hospital Dresden Germany
Department of Pediatrics Ghent University Hospital Ghent Belgium
Department of Pediatrics Prince of Wales Hospital Chinese University of Hong Kong Hong Kong China
Department of Pediatrics Rigshospitalet University Hospital Copenhagen Denmark
Department of Pediatrics Saint George Hospital University Medical Centre Beirut Lebanon
Dutch Childhood Oncology Group the Hague the Netherlands
INSERM Clinical Investigation Center 1402 Poitiers University Poitiers France
Citace poskytuje Crossref.org
